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We previously showed a decreased expression of vitamin D receptor (VDR) mRNA/protein in a small group of adrenocortical
carcinoma (ACC) tissues, suggesting the loss of a protective role of VDR against malignant cell growth in this cancer type.
Downregulation of VDR gene expression may result from epigenetics events, that is, methylation of cytosine nucleotide of CpG
islands in VDR gene promoter. We analyzed methylation of CpG sites in the VDR gene promoter in normal adrenals and
adrenocortical tumor samples. Methylation of CpG-rich 5󸀠 regions was assessed by bisulfite sequencing PCR using bisulfite-treated
DNA from archivalmicrodissected paraffin-embedded adrenocortical tissues.Three normal adrenals and 23 various adrenocortical
tumor samples (15 adenomas and 8 carcinomas) were studied. Methylation in the promoter region of VDR gene was found in
3/8 ACCs, while no VDR gene methylation was observed in normal adrenals and adrenocortical adenomas. VDR mRNA and
protein levels were lower in ACCs than in benign tumors, and VDR immunostaining was weak or negative in ACCs, including all
3 methylated tissue samples. The association between VDR gene promoter methylation and reduced VDR gene expression is not a
rare event in ACC, suggesting that VDR epigenetic inactivation may have a role in adrenocortical carcinogenesis.
1. Introduction
Besides the classical role in calcium and bone homeosta-
sis, 1𝛼,25-dihydroxycholecalciferol D3 [1𝛼,25(OH)
2
D
3
] (cal-
citriol), the active metabolite of vitamin D, has been recog-
nized to have “noncalcemic” effects in a variety of cells after
binding to vitamin D receptor (VDR, NR1I1), a member of
the nuclear receptor superfamily which includes receptors
for steroids, thyroid hormones, and retinoic acid [1]. The
VDR forms homodimers or heterodimers with the retinoid
X receptor (RXR, NR2B), to allow specific DNA binding.
The binding of 1𝛼,25(OH)
2
D
3
with VDR-RXR complex is
followed by the attachment of this complex to vitamin D
responsive elements, which then initiate transcription in the
promoter of target genes [2, 3]. The effect of liganded VDR
depends on the epigenetic landscape of target gene [4].
There is evidence that 1𝛼,25(OH)
2
D
3
protects against
tumor formation by several VDR-mediated mechanisms,
including regulation of growth arrest, cell differentiation,
migration, invasion, and apoptosis, making it a candidate
agent for cancer regulation [5–7]. A relationship between
the vitamin D system and the adrenal pathophysiology
and growth has been recently highlighted [8]. We showed
a decreased expression of VDR mRNA and protein in a
small group of human adrenocortical carcinomas (ACCs),
suggesting the loss of a protective role of VDR against
malignant cell growth, as suggested for other cancer types
[9, 10].
An aberrant global and gene-specific DNA promoter
methylation has been observed in human adrenocortical
tumors, either benign or malignant, implicating dysregu-
lation of steroid biosynthesis and adrenal growth [11–15].
Downregulation of VDR gene expression in adrenal carcino-
mas may result from epigenetic events, that is, methylation
of cytosine nucleotides in CpG island of VDR promoter. In
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fact, promoter methylation is able to distort the transcription
factor binding sites, causing transcriptional silencing.
In continuity with our previous observations [10], the aim
of our study was to analyze methylation of GpG sites in the
VDR gene promoter of a different and larger series of human
adrenocortical tissues, comparing adrenocortical adenomas
(ACAs) with ACCs samples.
2. Materials and Methods
2.1. Patients and Tissue Samples. This study was approved
by the institutional review board of the University Hospital
of Padova in accordance with the Declaration of Helsinki
guidelines as revised in 1983. Informed consent was obtained
from all individual participants included in the study. The
preoperative diagnosis was based on the clinical history,
symptoms, signs, endocrine evaluation, and imaging exam-
ination (e.g., MRI, CT). Archival microdissected paraffin-
embedded slides of the patients were used for histological
examinations and molecular studies. Diagnosis of adrenal
malignancy was performed according to the histopathologi-
cal criteria proposed byWeiss et al. [16] and the modification
proposed by Aubert et al. [17]. Three normal adrenal cortices
from adrenal glands of kidney donors were also studied.
Histopathological slides were classified by two pathologists
(R.C. and A.F.) independently, and no discrepancy existed
between them.
2.2. VDR Promoter Methylation Analysis. Total genomic
DNA was extracted from formalin-fixed paraffin embedded
(FFPE) adrenocortical tissues using QIAamp DNA FFPE
Tissue Kit (Qiagen, Milan, Italy). DNA samples underwent
bisulfite conversion using EZ DNA Methylation-Gold Kit
(Zymo Research Co., Milan, Italy). Bisulfite treatment pro-
duces a chemical conversion of unmethylated cytosine to
uracil, which is detected as a thymine after PCR.
Methylated cytosines are protected from chemical con-
version. Bisulfite-treatedDNAwas amplified using two sets of
bisulfite sequencing primers designed by using MethPrimer
(http://www.urogene.org/methprimer/index1.html) encom-
passing the region from −693 bp to −65 bp upstream VDR
transcription start site.
Primer sequences are as follows:
M1F 5󸀠-GGAATTCGGGATTAGGGATTAGGG-
AAG-3󸀠.
M1R 5󸀠-AATACGTCACCCCCACCTAAACTA-
ACCAAAC-3󸀠.
M2F 5󸀠-GTTAGTCGCTAGGCGTTTTTTAGC-
GTTTCGC-3󸀠.
M2R 5󸀠-TATAAAACAAAATTATCGATAATT-
ATAAATA-3󸀠.
M3F 5󸀠-GTAGAATTACGGTAGGAAGGGTGG-
GGGGTTG-3󸀠.
M3R 5󸀠-CCCCGCCCACAAATCCAATCCTCT-
CTTAGG-3󸀠.
PCR products were separated by electrophoresis and
isolated using a Centri-Sep Columns (Princeton Separations,
Milan, Italy). DNA was sequenced using the Reverse Primer
(M1R and M2R) with an Applied Biosystems automated
fluorescent sequencer (Applied Biosystems, Milan, Italy). In
DNA sequence, methylated sites were visually counted.
2.3. RNA Isolation/Quantitative Real-Time PCR (qPCR).
Total cellular RNA was extracted from FFPE adrenal tissue
slide samples using RNeasy Universal kit (Qiagen, Gaith-
ersburg, MD). Briefly, FFPE tissue was deparaffinized and
treated with proteinase K, and genomic DNA was removed
for total RNA extraction. Total RNAwas quantified by Nano-
Drop 1000 Spectrometer (ThermoScientific, Wilmington,
DE). Quality of RNA was analyzed by Agilent Bioanalyzer
2100 (Agilent Technologies, Palo Alto, CA). Evaluation of
gene expression was performed by quantitative RT-PCR, as
previously described in our recent publication [10]. Quanti-
tative PCR for VDR and the housekeeping HMBS (hydrox-
ymethylbilane synthase) gene primers were as follows: 5󸀠-
GAAGCCTTTGGGTCTGAAGTG-3󸀠 (VDR forward), 5󸀠-
CCGCCATTGCCTCCATCC-3󸀠 (VDR reverse) and 5󸀠-
GGCAATGCGGCTGCAA-3󸀠 (HMBS forward), 5󸀠-GGG-
TACCCACGCGAATCAC-3󸀠 (HMBS reverse). The anneal-
ing temperature was 60∘C for all genes. PCR was carried
out using a DNA Engine (Opticon 2 continuous fluorescence
detection system, MJ Research, Waltham, MA, USA). For
each sample, results were normalized with the HMBS rRNA.
2.4. Western Blot and Densitometric Analysis. Adrenal tissue
slides were deparaffinized using Xylene (Sigma) for 3 ×
10min and protein was extracted using Qproteome FFPE
Tissue kit (Qiagen, Milan, Italy) and slides were subjected
to western blot analyses by 10% Tris-HCl polyacrylamide
gel electrophoresis (PAGE) (Invitrogen Co., Eugene, OR,
USA) in running buffer (Tris/Glycine/SDS). Membranes
were probed at 4∘C overnight with anti-VDR mouse poly-
clonal antibody (1 : 500, VDR-D6, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) and mouse 𝛽-actin, Clone AC-
15 (1 : 10.000) (Sigma–Aldrich, St. Louis, MO, USA). Primary
anti-VDR and anti-𝛽-actin antibodies were detected with
a secondary goat anti-mouse fluorescent antibody (IRDye
800CW, Li-Cor Biosciences, Milan, Italy) (1 : 15.000). Signal
was acquired by Li-Cor Odyssey Clx (Li-Cor Biosciences).
Quantification of individual protein bands was measured by
Li-Cor Image Studio Digits. For each sample, results were
normalized with the housekeeping protein 𝛽-actin.
2.5. Immunohistochemistry. Immunostaining for VDR pro-
tein expression was performed in formalin-fixed paraffin-
embedded adrenal tissue slides, as described in our recent
publication [10]. Immunostaining was performed by the
streptavidin-biotin amplification method using a Histfine
Kit (Nichirei Co. Ltd., Tokyo, Japan). Antigen retrieval
was performed by heating the slides in an autoclave for
5min in citric acid buffer (2mM citric acid and 9mM
trisodium citrate dehydrate, pH 6.0). The dilution of the
primary antibodies was 1 : 50. The antigen-antibody complex
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Table 1: Clinical and tumor characteristics of the ACC patients analyzed in this study.
Sample ID Age Gender Stage at surgery(ENSAT)
Hormonal
hypersecretion Weiss score Size (mm) Outcome
C1 58 M III Cortisol 6 180 Died for recurrence 4years after surgery
C2 51 F III Cortisol 5 90 Alive, with recurrence
C3 36 M III Cortisol 9 110 Died for recurrence 6months after surgery
C4 73 M III Nonfunctioning 9 150 Died for recurrence 1year after surgery
C5 52 F IV Nonfunctioning 10 150 Died for recurrence 2years after surgery
C6 33 F III Cortisol 8 140 Alive, with recurrence
C7 51 M III Nonfunctioning 6 60 Alive, with recurrence
C8 68 M II Cortisol 9 80 Died for recurrence 2years after surgery
was visualized with 3,3󸀠-diaminobenzidine solution [1mM
3,3󸀠-diaminobenzidine, 50mM Tris-HCl buffer (pH 7.6),
and 0.006% H
2
O
2
] and counterstained with hematoxylin.
A human breast cancer specimen was used as a positive
control.Negative controlswere incubatedwith normalmouse
antiserum instead of the primary antibody, which uniformly
demonstrated no reaction (not shown).
2.6. Statistics. For two-sample comparison, differences
betweenmeans were assessed byMann-Whitney𝑈 test. Rela-
tionships between continuous variables were assessed calcu-
lating Spearman’s rank correlation coefficient. All results are
expressed as mean ± SD for continuous variables. 𝑃 values
<0.05 were taken as statistically significant. Statistical anal-
ysis was performed using the GraphPad Prism version 6.0
software (GraphPad Software).
3. Results
Twenty-three patients (12 females, 11 males) who underwent
adrenalectomy for sporadic adrenocortical tumors between
2006 and 2014 were classified as ACAs (𝑛 = 15) and ACCs
(𝑛 = 8). The cohort was different from that described in our
previous publication [10]. Fifteen patients withACA included
2 cortisol-producing adenomas, 10 aldosterone-producing
adenomas, and 3 nonfunctioning adenomas: 7 were females
and 8 males, ranging from 31 to 67 years of age (mean age of
51.3 years at presentation). Eight ACCs consisted of 5 females
and 3 males, ranging from 33 to 73 years of age (mean age of
52.7 years).
Clinical and tumor characteristics of the 8 ACC patients,
including ENSAT stage at surgery [18], are shown in
Table 1. Five ACCs patients had endocrine symptoms and
signs of excess cortisol secretion; three patients had non-
functioning adrenal mass. All patients with ACCs were
treated with the adrenolytic drug mitotane, 1,1-dichloro-
2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane (o,p󸀠-DDD),
before surgery. Specifically, mitotane was given before
surgery to the five patients with Cushing’s syndrome because
of hypercortisolism not amenable by other inhibitors of
steroidogenesis; the remaining 3 patients were treated with
mitotane as adjuvant therapy before second operation for
recurrent disease. Mean adrenal tumor diameter in ACAs
and ACCs group was 14mm and 120mm, respectively. Mean
postsurgery follow-up of patientswas 72months (range of 12–
120months) forACAs and 26months (range of 6–48months)
for ACCs.
Methylation in the VDR promoter was observed in 3/8
ACCs specimens,which included two cortisol-producing and
1 nonfunctioning carcinomapatients (C3,C4, andC6patients
in Table 1). Two PCR products, including region from −693
to −65 bp, contained 42 CpG islands, and 27 of them (64%)
were methylated. One representative case is presented in
Figure 1. Methylation sites were identical in all 3 ACCs tissue
specimens. No VDR promoter methylation was found in the
other 5 ACCs, 3 normal adrenals, and the 15 ACAs.
qPCR analysis demonstrated variable levels of VDR
mRNA in all adrenal tumors, with VDRmRNA expressed
at higher levels in ACAs than in ACCs (0.41 ± 0.2 versus
0.11 ± 0.08 arbitrary units, 𝑃 < 0.01) (Figure 2(a)). VDR
immunoblot in representative cases of a normal adrenal
(NA), ACAs, and ACCs is shown in Figure 2(b). VDR/𝛽-
actin protein levels, measured in the entire series of tumor
specimens, showed results similar to VDRmRNA in terms of
difference between benign and malignant tumors (0.20 ± 0.2
versus 0.04 ± 0.06 arbitrary units, 𝑃 < 0.05) (Figure 2(b)).
Low or absent VDR expression was observed in individual
cases of either ACAs or in ACCs. A positive correlation
between VDR mRNA and VDR/𝛽-actin levels (𝑃 < 0.003)
was observed (Figure 2(c)).
Immunohistochemical staining for VDR of representa-
tive cases of one normal adrenal, one ACA, and one of
the 3 methylated ACCs is reported in Figure 2(d). Both
nuclear and cytoplasmic VDR immunostaining, consistent
with translocation of VDR from cytoplasm to the nucleus
after ligand binding [10], were observed in the 3 normal
adrenals and in ACAs. At variance, expression of VDR was
undetectable or very weak and limited to only scattered
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GGAAGGCGGA ATTCGGGATT AGGGATTAGG GAAGTTGAGA TTTAGTTTTT TTGGGTGAGA 
TTCGCGATAG GTCGGGAACG TGGTTAGTCG CGGTCGTTGT TAAGGTGATA TCGGGTGGGA
GTAATGACGT AATTTCGGTT TTTATTTCGG TTTTTCGGGA TATTTTATTT TAATTTGTGG
GATTAGGTTG AGTTTTTTGG CGTTTTGTAG TAGTAATAGG TTGGCGAGCG GAGTTCGGGA
TTTTTTATTC GTGCGGAGTT AGTCGTCGGT GTTAGTCGGT AGGCGTTTTT TAGCGTTTCG
CGGACGACGA AGTTTTGGTT TGGTTAGTTT AGGTGGGGGT GACGTATTTG GTTTAGGCGT
TCGTAGTAGG TTGGGTAGAA TTACGGTAGG AAGGGTGGGG GGTTGTATTT TCGATTAATA
TAGGTTGAAG CGGGTATTCG TATTTATAAT TATCGATAAT TTTGTTTTAT AGAGGGTAGA
AGCGTGTTTT GTTTTATGGA CGACGGTCGA TGAAAATTTT ACGAGTTAGA GTATTTAAGG
TTATAGCGTG GTTTATAGGG TGGTTGATTT TAAGTTAAGA TGGTTGTAGC GTTAACGGAG
TTTTTGGTAA GAGAGGATTG GATTTGTGGG CGGGGCGGAG GGGCGGGGCG GGGTCGGGGC
GGGGTTTGAT CGAGAGGCGG GGTTAGGTGT TGGGTTGTTT−39
−99
−159
−219
−279
−339
−399
−459
−519
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−639
−699
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∘
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−65
Figure 1: VDR methylated sites of VDR promoter region from −693 to −65 bp in one representative adrenocortical carcinoma, analyzed by
bisulfite sequencing. In DNA sequence, bold types indicate all CpG dinucleotides, and underlined CpG indicate methylated sites.
tumor cells in all ACCs, including the 3 methylated cases
(Figure 2(d)).
4. Discussion
The reduced-absent expression of VDR mRNA and pro-
tein in adrenocortical cancer may be caused by different
molecular mechanism. A somatic VDR gene mutation could
occur, reflecting a mechanism (i.e., loss of tumor-suppressor
function) implicated in the malignant transformation of
adrenocortical cells. We did not analyze this possibility
in our samples, but VDR gene is rarely mutated during
carcinogenesis [19]. No evidence for VDR gene mutation in
a recent whole-exome sequencing analysis of a very large
number of ACCs [20] makes however unlikely this event.
Epigenetic inactivation of human VDR, reducing its mRNA
and protein expression, has been shown in various cancer
types [4, 21], supporting the loss of an antiproliferative
role of VDR [10], and may potentially occur in ACCs. The
promoter of VDR gene lies in a GC-rich island and contains
strong regulatory elements for its transcriptional activity [22].
Disruption of promoter activity by DNA methylation is an
epigenetic inactivating mechanism frequently observed in
tumor-suppressor genes [23]. Our present results support a
VDR silencing through this epigenetic mechanism in a sub-
group of ACCs. Since a growing body of evidence indicates
that DNA promotermethylation can be a consequence rather
than a cause of transcriptional inactivation, the hypothesis of
VDR methylation as the result of malignant transformation
cannot be also excluded. Moreover, methylation of VDR
promoter has not been specifically reported in all genome-
wide methylation studies on adrenocortical cancer [12–14].
Different epigenetic mechanisms explaining the down-
regulation of VDR gene expression can also be hypothesized
for our remaining ACCs and for some of our adenoma
cases with low VDR expression. Altered activity of regulatory
elements of VDR transcriptional activity, such as repres-
sors/corepressors or unbalanced enhancers, could be consid-
ered [4, 24]. Furthermore, the VDR gene promoter contains
an array of putative binding sites for transcription factors
mediating the activities of PKA and PKC pathways [22] that
are in turn known to converge on several specific transcrip-
tion factors.Themechanism of action of the liganded VDR is
also dependent on a plethora of enzymes regulating covalent
histone modifications, and this epigenetic regulatory system
has been found frequently altered in cancer.
We cannot exclude that low expression of VDR gene in
adrenocortical cancers, as well as in some benign adenomas,
may rather be due to the effect of hormonal compounds, that
is, estrogens, thyroid hormone, and glucocorticoids, which
are likewise able to alter VDR mRNA/protein levels [3].
Interestingly, we showed a critical role of estrogens and ER𝛼
in adrenal tumorigenesis [25]. Moreover, mitotane, the drug
used for treatment of all our ACC patients, is known to
stimulate CYP3A4 expression, potentially leading to reduced
1𝛼,25(OH)
2
D
3
bioavailability and reduced VDR expression
in adrenals [10]. There is also evidence that a number of
short noncoding RNAsmay repress VDR posttranscriptional
regulation in cancer [26], and their specific role as VDR
regulators in adrenocortical tumors is possible [27].
5. Conclusions
The main limitation of our study is the relatively small
number of samples, and a larger ACCs study population is
needed to confirm our results. The study could be enlarged
using the adrenal tissue bank of ENSAT (European Network
on Adrenal Tumors) collaborative group, which is dedicated
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Figure 2: Expression of VDR in normal human adrenals, in adrenocortical adenomas (ACAs), and in adrenocortical carcinomas (ACCs).
(a) Individual mRNA levels and means (horizontal bars) of VDR, measured by qPCR, in normal adrenals (𝑛 = 3), ACAs (𝑛 = 15), and
ACCs (𝑛 = 8). (b) VDR immunoblot (above) in representative cases of a normal adrenal (NA), ACAs, and ACCs, and individual VDR/𝛽-
actin protein levels (below) in normal adrenals, ACAs, and ACCs. (c) Correlation between VDR mRNA and VDR protein levels in all tissue
samples, including normal and neoplastic adrenal. (d) Immunohistochemical staining of VDR in a normal adrenal (left panel), one ACA
(central panel), and one methylated ACC (right panel), showing clear VDR expression in NA, in a cortisol-producing ACA, in both the
nucleus and predominantly the cytoplasm, and very weak VDR expression, limited to rare cells, in a cortisol-producing ACC. Sections were
counterstained with hematoxylin. Black dots indicate methylated tissue samples. Mann-Whitney 𝑡-test ACAs versus ACCs. ∗∗𝑃 < 0.01;
∗
𝑃 < 0.05. Spearman correlation 𝑟𝑠 = 0.56; 𝑃 < 0.003.
to the study and treatment of adrenal tumors, providing
study projects and enrolling research teams on this disease.
However, our findings represent the first evidence of an
association between VDR gene promoter methylation and
reduced VDR expression in ACC. This suggests a potential
role of VDR epigenetic inactivation in malignant adrenocor-
tical tumorigenesis. Adrenocortical carcinoma, either silent
or hormonally active, is a rare tumor with a very poor prog-
nosis, linked to its highly invasive phenotype and marked
resistance to radio- and chemotherapy [28]. The VDR pro-
moter methylation might be a target for pharmacological
agents to treat adrenal cancer in selected cases [29]. In this
regard, the human adrenocortical carcinoma H295R cell
line, which provides the most appropriate model for ACC
study [30], does not have VDR gene methylation (personal
observation). The availability of adrenal cell models allowing
the in vitro use of DNA methylation inhibitors should be
addressed.
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